ASX - Delayed Quote AUD

Zelira Therapeutics Limited (ZLD.AX)

Compare
0.6000 0.0000 (0.00%)
At close: 3:59:31 PM GMT+11

Key Executives

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.
NameTitlePayExercisedYear Born
Mr. Osagie O. Imasogie Esq. Founder & Chairman 144k -- 1962
Dr. Oludare Odumosu MD, Global CEO & Director 498.96k -- --
Mr. Greg Blake Executive Director 271.95k -- --
Mr. Timothy Ryan Slate Company Secretary & Non-Executive Director 36k -- --
Mr. Rahul Ganesan Vice President of Finance & Accounting -- -- --
Dr. Patty Washer Clinical Trial Consultant -- -- --

Zelira Therapeutics Limited

101 St Georges Terrace
Level 3
Perth, WA 6000
Australia
61 8 6558 0886 https://zeliratx.com
Sector: 
Healthcare
Industry: 
Biotechnology

Description

Zelira Therapeutics Limited, a biopharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of a variety of medical conditions in Australia and the United States. It offers formulations under the HOPE brand in Australia, Washington, Pennsylvania, and Louisiana, as well as develops Zenivol, a cannabinoid drug for the treatment of chronic insomnia. The company also provides over the counter products, including SprinJene, an oral care product; and acne treatment products under the RAF FIVE name, as well as Zyraydi, an enhanced distillate capture and dissolution matrix technology. In addition, it offers products for autism and chronic noncancer pain. The company was formerly known as Zelda Therapeutics Limited and changed its name to Zelira Therapeutics Limited in December 2019. Zelira Therapeutics Limited was incorporated in 2003 and is headquartered in Perth, Australia.

Corporate Governance

Zelira Therapeutics Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

February 20, 2025 at 10:59 AM UTC - February 24, 2025 at 12:00 PM UTC

Zelira Therapeutics Limited Earnings Date

Recent Events

Related Tickers